Trial · NCT04419259
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of erenumab on days of flushing | 12 weeks | Mean change in number of days with moderate, severe or extreme flushing from Baseline to week 12. Evaluated by the Flushing Assessment (FAST) Tool part II (moderate, severe or very severe flushing is defined as a score of 4-10 on FAST) |
| Secondary | Effect of erenumab on erythema | 12 weeks | Mean change in erythema from Baseline to week 4, 8 and 12. Will be evaluated by Clinicians Erythema Assessment (CEA) |
| Secondary | Effect of erenumab on quality of life: Dermatology Life Quality Index (DLQI) | 12 weeks | Mean change in quality of life from Baseline to week 4, 8 and 12. Will be evaluated by Dermatology Life Quality Index (DLQI) |
| Secondary | Proportion of patients that reach a 50% reduction in number of days with flushing | 12 weeks | To evaluate the proportion of patients with at least 50% reduction in number of days with moderate, severe or extreme flushing. Evaluated by the Flushing Assessment (FAST) Tool part II (moderate, severe or very severe flushing is defined as a score of 4-10 on FAST) |
| Secondary | Effect of erenumab on days of flushing | 8 weeks | Mean change in number of days with moderate, severe or extreme flushing from Baseline to week 4 and 8. Evaluated by the Flushing Assessment (FAST) Tool part II (moderate, severe or very severe flushing is defined as a score of 4-10 on FAST) |
| Secondary | Effect of erenumab on depression | 12 weeks | Mean change in depressive symptoms from Baseline to week 4, 8 and 12. Evaluated by Hospital Anxiety and Depression Scale (HADS). |
| Secondary | Effect of erenumab on overall rosacea symptoms | 12 weeks | Proportion of patients with Investigator's Global Assessment (IGA) '0' or '1' with an at least 2-point reduction from baseline to week 4, 8 and 12. |
| Secondary | Effect of erenumab on inflammatory lesions | 12 weeks | Mean change in Inflammatory Lesion Count (ILC) from baseline to week 4, 8 and 12 |
| Secondary | Proportion of patients that reach a 50% reduction in self-assessed rosacea symptoms | 12 weeks | Proportion of patients with at least 50% reduction in number of days with Patient's Self-Assessment (PSA) above 2 from Baseline to week 4, 8 and 12. |
| Secondary | Effect of erenumab on self-assessed rosacea symptoms | 12 weeks | Mean change in Patient's Self-Assessment (PSA) above 2 from Baseline to week 4, 8 and 12. |
| Secondary | Effect of erenumab on depressive symptoms | 12 weeks | Mean change in Quicky Inventory Depressive Symptomatology (QIDS) from Baseline to week 4, 8 and 12 |
| Secondary | Effect of erenumab on overall rosacea severity | 12 weeks | Mean change in overall rosacea severity from Baseline to week 4, 8 and 12. Evaluated by Rosacea Area and Severity Index (RASI) |
| Secondary | Effect of erenumab on rosacea symptoms | 12 weeks | Mean change in rosacea symptoms from Baseline to week 4, 8 and 12. Evaluated by Rosacea Clinical Scorecard (RCS) |
| Secondary | Effect of erenumab on rosacea-specific quality of life: Rosacea-specific Quality-of-Life index (RosaQoL) | 12 weeks | Mean change in rosacea-specific quality of life from Baseline to week 4, 8 and 12. Evaluated by the Rosacea-specific Quality-of-Life index (RosaQoL) |
| Other | Tolerability of erenumab in patients with rosacea | 12 weeks | To evaluate the tolerability of erenumab in patient with rosacea through assessment of adverse events at every visit from Baseline to week 4, 8 and 12. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04419259/registered